Laurus Labs Limited has entered into Share Subscription Agreement and Shareholders’ Agreement on November 23, 2022 with Ethan Energy India Private Limited for subscribing 7,40,000 equity shares of face value of Rs. 10 each at a premium of Rs. 42.70 which is equivalent to 26% of the paid up capital of Ethan Energy India Private Limited. 

 

This will enable the company to consume 100% of the solar energy to be supplied by Ethan Energy India Private Limited from their 10 MW Solar Energy plant. This is as per the policy of the government for captive consumption of power. 

 

Laurus Labs is a fully integrated pharmaceutical and biotechnology company with a leadership position in generic Active Pharmaceutical Ingredients (APIs) and a major focus on anti-retroviral, Hepatitis C, and oncology drugs. The company also develops and manufactures oral solid formulations, provides contract research and manufacturing services (CRAMS) to global pharma companies, and produces specialty ingredients for nutraceuticals, dietary supplements, and cosmeceuticals.

 

The company is passionate about advanced chemistry skills and has proven expertise in bringing innovative solutions, manufacturing efficiencies and unwavering quality focus which has won them long-standing relationships with our global customers. 

 

Laurus employs 5,700+ people, including around 790+ scientists at more than 8 facilities approved by major regulatory agencies USFDA, WHO-Geneva, UK-MHRA etc. During FY2022 Laurus generated over Rs. 4,900 crore in annual revenue.